Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients

The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-ter...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michael Kwan Leung Yu, Sophelia Hoi Shan Chan, Daniel Leung, Samuel Cheng, Leo Chi Hang Tsang, Tsz Chun Kwan, Kaiyue Zhang, Xiwei Wang, Wenwei Tu, Malik Peiris, Yu Lung Lau, Jaime S. Rosa Duque
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2024-12-01
Edice:	Human Vaccines & Immunotherapeutics
Témata:	BNT162b2 COVID-19 CoronaVac neuromuscular diseases immunogenicity
On-line přístup:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2424615
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!